350MO Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer – second interim efficacy analysis of the randomized phase III DETECT V trial [Abstract]
| Author: | W. Janni, T. N. Fehm, V. Mueller, A. M. B. de Gregorio, T. Decker, A. D. Hartkopf, M. Just, Jacqueline Sagasser, M. Schmidt, P. Wimberger, T. Engler, M. Banys-Paluchowski, P. A. Fasching, B. Rack, A. Schneeweiss, J.-U. Blohmer, J. Huober, K. Pantel, T. W. P. Friedl, F. Schochter |
|---|---|
| Frontdoor URL | https://opus.bibliothek.uni-augsburg.de/opus4/115578 |
| ISSN: | 0923-7534OPAC |
| Parent Title (English): | Annals of Oncology |
| Publisher: | Elsevier BV |
| Type: | Article |
| Language: | English |
| Year of first Publication: | 2024 |
| Publishing Institution: | Universität Augsburg |
| Release Date: | 2024/09/25 |
| Volume: | 35 |
| Issue: | Supplement 2 |
| First Page: | S362 |
| DOI: | https://doi.org/10.1016/j.annonc.2024.08.298 |
| Institutes: | Medizinische Fakultät |
| Medizinische Fakultät / Universitätsklinikum | |
| Medizinische Fakultät / Lehrstuhl für Frauenheilkunde |
